personalized neoantigen peptide vaccine + osimertinib

This is a combination therapy consisting of a personalized neoantigen peptide vaccine and osimertinib. The personalized neoantigen peptide vaccine is an individualized immunotherapy designed by identifying tumor-specific mutations (neoantigens) unique to each patient’s cancer, synthesizing peptides that match these sequences, and administering them as a vaccine to elicit a robust T-cell-mediated immune response against the tumor[5][6][10]. Osimertinib is an oral third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), primarily used in the treatment of non-small cell lung cancer with specific EGFR mutations. The rationale for combining these therapies is to leverage the targeted antitumor effects of osimertinib with the immune-activating properties of the personalized vaccine, potentially enhancing efficacy through synergistic mechanisms—targeting both oncogenic signaling and stimulating anti-tumor immunity[1][7]. This combination remains investigational; while similar combinations with other immunotherapies are in early-phase clinical trials, there are no reports yet of advanced-phase studies specifically for this exact pairing.